CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.
Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本前瞻性单中心队列纳入接受阿基仑赛或替沙妥仑赛治疗的大B细胞淋巴瘤患者,于基线、输注后1个月及3个月采集[18F]FDG PET/CT影像。采用SUVmax≥4的阈值计算MTV和TLG。随访总生存期(OS)、无进展生存期(PFS)及缓解持续时间(DoR),影像评估依据Lugano应答评估标准;通过单变量和多变量Cox回归识别预后因素。
共纳入61例,中位随访18个月;28例(46%)死亡。Kaplan-Meier分析和log-rank检验显示,Deauville评分(DS)、SUVmax、MTV及TLG升高均与OS显著相关(均P<.05);DS截断值设为4。PET1m时SUVmax、MTV和TLG的最佳截断值分别为9.1、60.8和97.0;PET3m时分别为6.3、120.1和436.9。PET3m SUVmax≥6.3者死亡风险为低于该截断值者的8倍(HR 8.15,95% CI 2.81–23.6,P<.01);PET3m MTV较高(≥120.1)者死亡风险接近10倍(HR 9.87,95% CI 3.65–26.7,P<.01)。PET1m和PET3m的DS、SUVmax、MTV及TLG均与OS和PFS相关(均P<.05),PET3m参数还与DoR相关(P<.05)。PET3m指标的Harrell C指数高于PET1m,但差异无统计学意义(P>.05)。多变量分析显示,年龄较大(HR 1.10)、桥接治疗(HR 10.91)、乳酸脱氢酶升高(HR 6.43)、纤维蛋白原升高(HR 5.27)及PET3m SUVmax较高(HR 11.03)可独立预测较差OS。SUVmax、MTV和TLG与CAR-T 相关毒性无显著关联。
CAR-T 治疗后1个月和3个月的SUVmax、MTV和TLG等半定量PET参数均与OS、PFS和DoR显著相关。输注后3个月的[18F]FDG PET/CT可能具有略强的预后区分能力,但两个时间点均可用于早期风险分层。
Chimeric antigen receptor T-cell (CAR T) therapy has shown remarkable efficacy in treating relapsed or refractory large B-cell lymphoma.
However, for nearly half of these patients, the therapy eventually does not achieve durable remission.
We investigated whether semiquantitative PET parameters (namely, SUV max , metabolic tumor volume [MTV], and total lesion glycolysis [TLG]) could improve risk stratification 1 mo (PET1m) and 3 mo (PET3m) after CAR T infusion. Methods: In this prospective, single-center cohort study, patients with large B-cell lymphoma received axicabtagene ciloleucel or tisagenlecleucel. [ 18 F]FDG PET/CT scans were acquired at baseline, 1 mo, and 3 mo after infusion. MTV and TLG were calculated using a threshold SUV max of 4 or greater. Patients were followed for overall survival (OS), progression-free survival (PFS), and duration of response (DoR). The imaging assessment was based on the Lugano recommendation for response assessment. Prognostic factors were identified using univariate and multivariate Cox regression. Results: Sixty-one patients were enrolled, with a median follow-up of 18 mo. Twenty-eight (46%) patients died. Kaplan-Meier analysis with log-rank tests indicated a significant association of elevated Deauville score (DS), SUV max , MTV, and TLG with OS (all P < 0. 05). DS cutoff was arbitrarily fixed at 4. The optimal SUV max , MTV, and TLG cutoffs at PET1m were 9. 1, 60. 8, and 97. 0, respectively; whereas at PET3m, they were 6. 3, 120. 1, and 436.
9, respectively. Patients with an SUV max of 6. 3 or greater at PET3m had an 8-fold increase in risk of death (hazard ratio [HR], 8. 15; 95% CI, 2. 81-23. 6; P < 0. 01) compared with those below this cutoff. Similarly, higher MTV ( 120. 1) at PET3m yielded a nearly 10-fold risk (HR, 9. 87; 95% CI, 3. 65-26. 7; P < 0. 01). DS, SUV max , MTV, and TLG at both PET1m and PET3m were associated with OS and PFS (all P < 0. 05), whereas PET3m parameters also correlated with DoR ( P < 0. 05). Harrell C-index values were higher for PET3m measures than for PET1m, though differences were not statistically significant ( P > 0. 05).
On multivariable analysis, older age (HR, 1. 10), bridging therapy (HR, 10. 91), elevated lactate dehydrogenase (HR, 6. 43), increased fibrinogen (HR, 5. 27), and higher SUV max at PET3m (HR, 11. 03) independently predicted poorer OS. There were no significant associations between SUV max , MTV, and TLG with CAR T-related toxicities.
Conclusion: Semiquantitative PET parameters, such as SUV max , MTV, and TLG, at 1 mo and 3 mo after CAR T-cell therapy correlate significantly with OS, PFS, and DoR. [ 18 F]FDG PET/CT at 3 mo may offer slightly stronger prognostic discrimination, but both time points can be used for early risk stratification.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。